HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Geoffrey T Yarranton Selected Research

N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicin

9/2003CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
4/2002CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Geoffrey T Yarranton Research Topics

Disease

2Neoplasms (Cancer)
09/2003 - 04/2002
1Leukemia
09/2003
1Carcinoma (Carcinomatosis)
09/2003
1B-Cell Lymphoma (Lymphoma, B Cell)
09/2003

Drug/Important Bio-Agent (IBA)

2N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicinIBA
09/2003 - 04/2002
2Doxorubicin (Adriamycin)FDA LinkGeneric
09/2003 - 04/2002
2ProdrugsIBA
09/2003 - 04/2002
1Metalloproteases (Metalloproteinases)IBA
09/2003
1Peptide Hydrolases (Proteases)FDA Link
09/2003
1Peptides (Polypeptides)IBA
09/2003
1EnzymesIBA
09/2003

Therapy/Procedure

2Therapeutics
09/2003 - 04/2002
1Aftercare (After-Treatment)
04/2002